Immunitybio is trading 4.1% down at $7.88 as traders continue to digest the impact of an FDA warning letter regarding Anktiva promotional practices and the resulting risk of class-action lawsuits.
- The move reflects ongoing risk repricing following a significant year-to-date rally, with no fresh company-specific headlines reported today.
- Downward pressure is being amplified by a broader selloff in the U.S. markets and sector-wide profit-taking across the biotech industry.